newsfilter
← Latest News
GlobeNewswire·

Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance

  • Sanuwave Health expects Q2 2026 revenues to range between $9.6 million & $9.8 million, exceeding the revised guidance high end of $9.5 million.
  • Preliminary Q2 revenues represent a 3–5% decrease compared to $10.1 million reported in Q2 2025.
  • CEO Morgan Frank attributed capital sales headwinds to customer base stress & the market sale of used Ultramist systems.
  • The company implemented a program to qualify, train, & support new users of used systems, offering trade-in terms for certified pre-owned units with manufacturer warranties.
  • Sales of consumable applicators set all-time records for both unit volume & revenue in the quarter.
  • Preliminary results are based on management's initial analysis of the quarter ended June 30, 2026, & are subject to adjustment upon final financial close.